Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials

C. Malattia, N. Ruperto, S. Pederzoli, E. Palmisani, A. Pistorio, C. Wouters, P. Dolezalova, B. Flato, S. Garay, G. Giancane, C. Wells, W. Douglass, HI. Brunner, F. De Benedetti, A. Ravelli, Paediatric Rheumatology International Trials...

. 2020 ; 22 (1) : 211. [pub] 20200910

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020133

BACKGROUND: Few clinical trials have investigated the prevention of radiographic progression in children with juvenile idiopathic arthritis treated with antirheumatic drugs. This study aimed to investigate radiographic progression in patients with systemic juvenile idiopathic arthritis (sJIA) and patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with the anti-interleukin-6 receptor antibody tocilizumab for 2 years in the TENDER and CHERISH randomized controlled trials, respectively. METHODS: Standard radiographs of both wrists and both hands in the posteroanterior view were obtained within 4 weeks of baseline and were repeated at weeks 52 ± 4 and 104 ± 4 in both trials. All films were scored by two independent readers using the adapted Sharp-van der Heijde (aSH) and Poznanski scoring methods. Although the Poznanski score indicates bone growth limitation or cartilage growth decrease, which are not the same as joint space narrowing in rheumatoid arthritis, its change reflects damage to cartilage. Therefore, impairment in the Poznanski score as well as the aSH score was considered as a measure of structural joint damage. Radiographic progression was defined as worsening of radiographic scores beyond the smallest detectable difference. RESULTS: Poznanski and aSH scores were available at baseline and at one or more postbaseline time points for 33 and 47 of 112 sJIA patients and 61 and 87 of 188 pcJIA patients, respectively, providing a representative subset of the study populations. The inter-reader and intra-reader agreement intra-class correlation coefficient was > 0.8. Median baseline Poznanski and aSH scores, respectively, were - 2.4 and 24.6 for sJIA patients and - 1.5 and 8.0 for pcJIA patients. Compared with baseline, aSH scores remained stable for all sJIA patients at week 52, whereas 9.4% of sJIA patients had radiographic progression according to Poznanski scores at week 52; at 104 weeks, radiographic progression according to aSH and Poznanski scores was observed in 5.4% and 11.5%, respectively. In pcJIA patients, radiographic progression from baseline at 52 weeks and at 104 weeks was 12.5% and 2.9%, respectively, using aSH scoring and 6.5% and 4%, respectively, using Poznanski scoring. CONCLUSION: Tocilizumab may delay radiographic progression in children with sJIA and children with pcJIA. TRIAL REGISTRATION: Trial registration numbers and dates: TENDER, NCT00642460 (March 19, 2008); CHERISH, NCT00988221 (October 1, 2009).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020133
003      
CZ-PrNML
005      
20210830101739.0
007      
ta
008      
210728s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13075-020-02303-y $2 doi
035    __
$a (PubMed)32912276
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Malattia, Clara $u Università degli Studi di Genova, Genoa, Italy $u IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Via G. Gaslini 5, 16147, Genoa, Italy
245    10
$a Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials / $c C. Malattia, N. Ruperto, S. Pederzoli, E. Palmisani, A. Pistorio, C. Wouters, P. Dolezalova, B. Flato, S. Garay, G. Giancane, C. Wells, W. Douglass, HI. Brunner, F. De Benedetti, A. Ravelli, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
520    9_
$a BACKGROUND: Few clinical trials have investigated the prevention of radiographic progression in children with juvenile idiopathic arthritis treated with antirheumatic drugs. This study aimed to investigate radiographic progression in patients with systemic juvenile idiopathic arthritis (sJIA) and patients with polyarticular-course juvenile idiopathic arthritis (pcJIA) treated with the anti-interleukin-6 receptor antibody tocilizumab for 2 years in the TENDER and CHERISH randomized controlled trials, respectively. METHODS: Standard radiographs of both wrists and both hands in the posteroanterior view were obtained within 4 weeks of baseline and were repeated at weeks 52 ± 4 and 104 ± 4 in both trials. All films were scored by two independent readers using the adapted Sharp-van der Heijde (aSH) and Poznanski scoring methods. Although the Poznanski score indicates bone growth limitation or cartilage growth decrease, which are not the same as joint space narrowing in rheumatoid arthritis, its change reflects damage to cartilage. Therefore, impairment in the Poznanski score as well as the aSH score was considered as a measure of structural joint damage. Radiographic progression was defined as worsening of radiographic scores beyond the smallest detectable difference. RESULTS: Poznanski and aSH scores were available at baseline and at one or more postbaseline time points for 33 and 47 of 112 sJIA patients and 61 and 87 of 188 pcJIA patients, respectively, providing a representative subset of the study populations. The inter-reader and intra-reader agreement intra-class correlation coefficient was > 0.8. Median baseline Poznanski and aSH scores, respectively, were - 2.4 and 24.6 for sJIA patients and - 1.5 and 8.0 for pcJIA patients. Compared with baseline, aSH scores remained stable for all sJIA patients at week 52, whereas 9.4% of sJIA patients had radiographic progression according to Poznanski scores at week 52; at 104 weeks, radiographic progression according to aSH and Poznanski scores was observed in 5.4% and 11.5%, respectively. In pcJIA patients, radiographic progression from baseline at 52 weeks and at 104 weeks was 12.5% and 2.9%, respectively, using aSH scoring and 6.5% and 4%, respectively, using Poznanski scoring. CONCLUSION: Tocilizumab may delay radiographic progression in children with sJIA and children with pcJIA. TRIAL REGISTRATION: Trial registration numbers and dates: TENDER, NCT00642460 (March 19, 2008); CHERISH, NCT00988221 (October 1, 2009).
650    _2
$a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a juvenilní artritida $x diagnostické zobrazování $x farmakoterapie $7 D001171
650    _2
$a dítě $7 D002648
650    _2
$a progrese nemoci $7 D018450
650    _2
$a lidé $7 D006801
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ruperto, Nicolino $u IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Via G. Gaslini 5, 16147, Genoa, Italy
700    1_
$a Pederzoli, Silvia $u IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Via G. Gaslini 5, 16147, Genoa, Italy
700    1_
$a Palmisani, Elena $u IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Via G. Gaslini 5, 16147, Genoa, Italy
700    1_
$a Pistorio, Angela $u IRCCS Istituto Giannina Gaslini, Servizio di Epidemiologia e Biostatistica, Genoa, Italy
700    1_
$a Wouters, Carine $u University Hospital Gasthuisberg, Leuven, Belgium
700    1_
$a Dolezalova, Pavla $u General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Flato, Berit $u Oslo University Hospital and University of Oslo, Oslo, Norway
700    1_
$a Garay, Stella $u Hospital Sor Maria Ludovica, La Plata, Argentina
700    1_
$a Giancane, Gabriella $u IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Via G. Gaslini 5, 16147, Genoa, Italy
700    1_
$a Wells, Chris $u Roche Products Ltd., Welwyn Garden City, UK
700    1_
$a Douglass, Wendy $u Roche Products Ltd., Welwyn Garden City, UK
700    1_
$a Brunner, Hermine I $u Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
700    1_
$a De Benedetti, Fabrizio $u IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy
700    1_
$a Ravelli, Angelo $u Università degli Studi di Genova, Genoa, Italy. angeloravelli@gaslini.org $u IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Via G. Gaslini 5, 16147, Genoa, Italy. angeloravelli@gaslini.org $u Sechenov First Moscow State Medical University, Moscow, Russian Federation. angeloravelli@gaslini.org
710    2_
$a Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
773    0_
$w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 22, č. 1 (2020), s. 211
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32912276 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101739 $b ABA008
999    __
$a ok $b bmc $g 1690841 $s 1140579
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 22 $c 1 $d 211 $e 20200910 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace